Australia’s active vaccine safety system

On 1 November 2023, Shingrix® replaced Zostavax® on the National Immunisation Program schedule for the prevention of shingles and post-herpetic neuralgia. 

Shingrix® has been available to purchase privately for use in Australia since 2021 and has been shown to be safe and effective both in Australia and overseas. 

To support the rollout of Shingrix® to a broader population, AusVaxSafety is conducting enhanced active surveillance of Shingrix® across Australia to provide reassurance that the short-term safety profile of the vaccine is consistent with previous surveillance activities.

Surveillance data are gathered by AusVaxSafety surveillance tools and are based on vaccine safety surveys sent in the days following Shingrix® vaccination. Data on this page are updated monthly.


Latest Shingrix® vaccine safety data

Click on the tiles below to view AusVaxSafety Shingrix® safety data for specific population groups.